Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)

An Open-Label, Pharmacokinetic Study of the Safety and Tolerability of Pazopanib in Combination With FOLFOX 6 or CapeOx in Subjects With Colorectal Cancer

This study will test the safety of treating colorectal cancer with a combination of drugs. The current standard treatments of FOLFOX6 or CapeOx will be give in combination with the GSK investigational drug pazopanib.

Inclusion Criteria:

• Diagnosis of locally advanced or metastatic colorectal cancer.
• No prior chemotherapy for metastatic disease.
• Presence of radiologically and/or clinically documented disease.
• Eastern Cooperative Oncology Group performance status of 0 or 1.
• Adequate bone marrow, hepatic, renal function, Urine Creatinine Ratio (UPC) of <
• A female subject must not be pregnant or breast feeding.
• Able to swallow and retain oral medications.

Exclusion Criteria:

• Has had any major surgery, chemotherapy, hormone therapy, investigational agent, or radiotherapy within the last 28 days
• Prior treatment with pazopanib, or oxaliplatin.
• Known contraindications to the use of oxaliplatin, capecitabine, 5-fluorouracil, or folinic acid.
• Participation in any investigational study within 28 days prior to study treatment.
• Women who are pregnant or lactating.
• Poorly controlled hypertension.
• A history of cardiovascular disease, arrhythmias, or significant ECG abnormalities.
• Any history of stroke.
• Current use of therapeutic warfarin.
• Known brain metastases.
• History of disease significantly affecting gastrointestinal function or major resection of the stomach or small bowel.
• Active infections or other serious illness.
• History of allergy to platinum compounds or heparin.
• Poor venous access.